Literature DB >> 9353381

d-Methadone is antinociceptive in the rat formalin test.

N Shimoyama1, M Shimoyama, K J Elliott, C E Inturrisi.   

Abstract

The l-isomer of methadone possesses opioid activity, whereas the d-isomer is weak or inactive as an opioid. Both d- and l-methadone have been shown to bind to the N-methyl-D-aspartate (NMDA) receptor. To determine whether d-methadone has functional, in vivo NMDA receptor antagonist activity, the antinociceptive effects of d-methadone were evaluated in the rat tail-flick and formalin tests. Cumulative dose-response analysis in the tail-flick test revealed an ED50 value for intrathecal (spinal) l-methadone of 15.6 microg/rat. In contrast, spinal d-methadone produced no antinociception at a cumulative dose of 460 microg/rat. d-Methadone in a dose range from 32 to 320 microg/rat dose-dependently reduced formalin-induced flinching behavior during phase 2 but not during phase 1 of the formalin test. These antinociceptive effects of d-methadone were not blocked by a spinal dose of naloxone that effectively antagonized an antinociceptive (tail-flick test) dose of l-methadone. d-Methadone at an intrathecal dose of 250 microg shifted the ED50 value for NMDA-induced nociceptive behaviors more than 3-fold to the right, which indicates an antagonism of these NMDA receptor-mediated effects. These results indicate that d-methadone is antinociceptive as a result of its NMDA receptor antagonist activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9353381

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  Characterization of the antinociceptive effects of the individual isomers of methadone after acute and chronic administrations.

Authors:  Richard W Morgan; Katherine L Nicholson
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

Review 2.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 3.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  The opioid methadone induces a local anaesthetic-like inhibition of the cardiac Na⁺ channel, Na(v)1.5.

Authors:  V Schulze; C Stoetzer; A O O'Reilly; E Eberhardt; N Foadi; J Ahrens; F Wegner; A Lampert; J de la Roche; A Leffler
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

5.  Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure.

Authors:  Timothy B Mitchell; Kyle R Dyer; David Newcombe; Amy Salter; Andrew A Somogyi; Felix Bochner; Jason M White
Journal:  Br J Clin Pharmacol       Date:  2004-12       Impact factor: 4.335

6.  siRNA-mediated knockdown of the NR1 subunit gene of the NMDA receptor attenuates formalin-induced pain behaviors in adult rats.

Authors:  Sandra M Garraway; Qinghao Xu; Charles E Inturrisi
Journal:  J Pain       Date:  2009-01-29       Impact factor: 5.820

Review 7.  Interindividual variability of methadone response: impact of genetic polymorphism.

Authors:  Yongfang Li; Jean-Pierre Kantelip; Pauline Gerritsen-van Schieveen; Siamak Davani
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

Review 8.  Methadone: a new old drug with promises and pitfalls.

Authors:  Jodie A Trafton; Abhinav Ramani
Journal:  Curr Pain Headache Rep       Date:  2009-02

9.  The successful use of parenteral methadone in a patient with a prolonged QTc interval.

Authors:  Ryuichi Sekine; Eugenie A M T Obbens; Nessa Coyle; Charles E Inturrisi
Journal:  J Pain Symptom Manage       Date:  2007-07-05       Impact factor: 3.612

Review 10.  Emerging Challenges to the Safe and Effective Use of Methadone for Cancer-Related Pain in Paediatric and Adult Patient Populations.

Authors:  Kyle P Edmonds; Ila M Saunders; Andrew Willeford; Toluwalase A Ajayi; Rabia S Atayee
Journal:  Drugs       Date:  2020-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.